US Dept of Defense awards $140M contract to Tekmira Pharmaceuticals conducting clinical trials on Ebola drug
Ziopharm and Solasia Pharma announce global license and collaboration agreement for darinaparsin
Visit our sites for b2b sales and banking employees:
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Endo Health Solutions | 1 | 7 | 600 % |
| Durata Therapeutics | 1 | 5 | 400 % |
| Ascenta | 1 | 5 | 400 % |
| Bacterin International Holdings | 1 | 4 | 300 % |
| Tekmira Pharmaceuticals | 1 | 4 | 300 % |
| Mylan | 6 | 20 | 233 % |
| Valeant Pharmaceuticals | 4 | 13 | 225 % |
| Amarantus BioSciences | 1 | 3 | 200 % |
| Auxilium | 1 | 3 | 200 % |
| McKesson | 3 | 9 | 200 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| Threshold Pharmaceuticals | 2 | 28 | 1300 % |
| Shanghai Pharmaceutical | 1 | 12 | 1100 % |
| Cambrex Corp | 2 | 19 | 850 % |
| Alphatec Holdings | 3 | 25 | 733 % |
| Delcath | 2 | 15 | 650 % |
| Digirad | 4 | 29 | 625 % |
| CelSci | 2 | 14 | 600 % |
| Spectrum Pharmaceuticals | 15 | 98 | 553 % |
| Animal Health International | 5 | 31 | 520 % |
| Cel-Sci | 8 | 45 | 463 % |